Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial.

Autor: Seufferlein, Thomas1 (AUTHOR) thomas.seufferlein@uniklinik-ulm.de, Lausser, Ludwig2,3 (AUTHOR), Stein, Alexander4 (AUTHOR), Arnold, Dirk5 (AUTHOR), Prager, Gerald6 (AUTHOR), Kasper-Virchow, Stefan7 (AUTHOR), Niedermeier, Michael8 (AUTHOR), Müller, Lothar9 (AUTHOR), Kubicka, Stefan10 (AUTHOR), König, Alexander11 (AUTHOR), Büchner-Steudel, Petra12 (AUTHOR), Wille, Kai13 (AUTHOR), Berger, Andreas W.1 (AUTHOR), Kestler, Angelika M. R.1 (AUTHOR), Kraus, Johann M.2 (AUTHOR), Werle, Silke D.2 (AUTHOR), Perkhofer, Lukas1 (AUTHOR), Ettrich, Thomas J.1 (AUTHOR), Kestler, Hans A.2 (AUTHOR) thomas.seufferlein@uniklinik-ulm.de
Zdroj: PLoS ONE. 6/14/2024, Vol. 19 Issue 6, p1-16. 16p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje